Blood
Articles in this Issue
Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial
Abstract INTRODUCTION: Regulatory and health technology assessment (HTA) agencies (including G-BA) are emphasizing patient-focused outcomes,...
Addressing functional asplenia in sickle cell disease: A quality improvement approach to improve vaccination rates
Abstract Background: Vaso-occlusion in sickle cell disease (SCD) leads to functional asplenia, increasing severe infection risk from encapsu...
Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis
Abstract Background: Elotuzumab, a monoclonal antibody targeting SLAMF7, demonstrated improved response rates and overall survival (OS) in c...
GPRASP2 maintains hematopoietic stem cell quiescence and self-renewal by receptor-mediated endocytosis
Abstract The hematopoietic stem cell (HSC) compartment is highly heterogeneous in terms of functional diversity. Deeply quiescent HSCs, whic...
Development of a NO probe cell imaging method based on CD58 expression in diffuse large B-cell lymphoma and as a tool to predict CAR-T efficacy
Abstract Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has significantly altered the treatment landscape for various h...
Targeted lnp delivery of an RNA gene writer In Vivo enables generation of functional CAR-T cells
Abstract Autologous ex vivo Chimeric Antigen Receptor (CAR) T-cell therapies are a powerful treatment option for relapsed and refractory leu...
Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is)
Abstract INTRODUCTION Advances in targeted therapies have resulted in extended survival for many pts with CLL/SLL. OS is a key endpoint in on...
Association between helicobacter pylori infection and immune thrombocytopenia in chronic lymphocytic leukemia: A retrospective cohort study
Abstract Background Immune thrombocytopenia (ITP) is a known autoimmune complication in chronic lymphocytic leukemia (CLL), likely driven by...
Precision targeting of autoantibody-producing IGHV1-69+ B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP) using chimeric antigen receptor T cells
Abstract Introduction : CD19-directed Chimeric Antigen Receptor T cell (CART19) immunotherapy has shown promise for the treatment of B cell-...
Novel immune gene expression signature risk-stratifies Mantle Cell Lymphoma outcomes independent of TP53 status
Abstract Background: The prognostic impact of specific genomic changes in mantle cell lymphoma (MCL) is not well characterized beyond altere...
Secretory phospholipase A2 (sPLA2) during vaso-occlusive pain episodes (VOE) and acute chest syndrome (ACS) in sickle cell disease (SCD): Results from a prospective multi-center randomized controlled trial (RCT)
Abstract Background: Acute chest syndrome (ACS) is the leading cause of morbidity and mortality in children with SCD, often developing durin...
Healthcare costs associated with hematopoietic cell transplant for sickle cell disease in the United States and Canada: A comparative analysis
Abstract Background: In the last decade, options for treatment of sickle cell disease (SCD) have grown remarkably with the development of ne...
Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)
Abstract ELN recommendations for AML diagnosis, genetic risk stratification and treatment have been updated in 2022. Accordingly, FLT3-ITD+...
Anatomical localization-based analysis of de novo secondary cns lymphoma
Abstract Background: De novo secondary central nervous system (CNS) lymphoma (SCNSL), characterized by concurrent systemic and CNS aggressive...
Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)
Abstract Introduction: ADVANCE (NCT04268498) is a fully enrolled, ongoing trial for patients with newly diagnosed multiple myeloma (NDMM). P...
EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis
Abstract Background Watchful waiting is a common option for pts with asymptomatic FL/MZL. Anti-tumor immunization may delay or even avoid su...
Multiplex detection of gastrointestinal microbiota using short probes in graft vs. host disease
Abstract Background: Association of bacterial taxa to graft vs. host disease (GVHD) have relied on examination of fecal samples, but tissue...
Extranodal involvement of the gastrointestinal tract in post transplant lymphoproliferative disorders: Stomach or small bowel involvement increases mortality risk
Abstract Post transplant lymphoproliferative disorder (PTLD) is a group of heterogeneous lymphoid disorders that represent a clinically sign...
Real world treatment outcome with azacytidine (AZA)-tocilizumab (TCZ) for reducing steroid dependence in vexas syndrome with myelodysplastic syndrome (MDS): A single-center, 1.5-year longitudinal observational study
Abstract Background: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a rare, adult-onset autoinflammatory disor...
Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis
Abstract Background: Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous disease with variable pro...
Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd
Abstract Background: Early treatment of HR-SMM has been shown to delay progression to symptomatic myeloma. In the phase II GEM-CESAR trial,...
Prevalence of TPMT and NUDT15 diplotypes in Mexican children with B-cell acute lymphoblastic leukemia
Abstract Introduction: B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer worldwide and the leading cause of can...
Comparative efficacy of complement inhibitors in complement Inhibitor–Naïve PNH: A network meta-analysis of randomized trials
Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon, life-threatening disease, caused by intravascular hemolysis...
Clonal persistence and early cooperative mutations shape transformation in myelofibrosis
Abstract Background Myeloproliferative neoplasms (MPNs) can progress from chronic phase to accelerated or blast phase (MPN-AP/BP), a transit...
Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL
Abstract Introduction: CD19 chimeric antigen receptor T-cell (CAR-T) therapy yields high remission rates in adult B-cell acute lymphoblastic...